Table 2 The comparison of fibrin clot proprieties.

From: Accelerated fibrin clot degradation is associated with arterial thromboembolism in patients following venous thrombosis: a cohort study

Variable

All patients (n = 310)

Non-ATE patients (n = 289)

Patients with ATE (n = 21)

P

Patients without recurrent VTE and ATE during follow-up (n = 211)

Patients with recurrent VTE*(n = 83)

Patients with ATE (n = 16)

P

Ks, 10–9 cm2

7.4 (6.5–7.9)

7.4 (6.6–8)

6.8 (6.4–7)

0.036

7.5 (6.9–8.1)

6.6 (6.1–7.3)

7 (6.6–7.5)

 < 0.001†

Lag phase, s

43 (39–46)

43 (39–46)

43 (37–46)

0.58

44 (40–47)

40 (35–44)

43.5 (37.5–46)

 < 0.001†

ΔAbs

0.81 (0.77–0.85)

0.81 (0.77–0.85)

0.83 (0.8–0.86)

0.09

0.8 (0.76–0.85)

0.83 (0.78–0.87)

0.83 (0.8–0.87)

0.043†

D-Dmax, mg/L

4.07 (3.68–4.39)

4.07 (3.68–4.34)

4.31 (3.8–4.42)

0.17

4.07 (3.64–4.32)

3.98 (3.69–4.41)

4.32 (4.15–4.46)

0.05

D-Drate, mg/L/min

0.072 (0.068–0.079)

0.072 (0.068–0.079)

0.077 (0.071–0.083)

0.017

0.072 (0.069–0.08)

0.069 (0.066–0.073)

0.077 (0.071–0.083)

 < 0.001† 0.002‡

CLT, min

86 (74–99)

86 (74–99)

82 (70–95)

0.41

81 (71–94)

100 (90–108)

75 (68.5–89)

 < 0.001†‡

  1. Ks, fibrin clot permeability; ΔAbs, maximum absorbance at the plateau phase; D-Dmax, maximum D-dimer concentrations; D-Drate, rate of increase in D-dimer levels; CLT, clot lysis time; for other abbreviations see Table 1. Values are given as median (interquartile range). In terms of ATE two patients excluded from the previous analysis were included in the current follow-up study.
  2. *Five patients with both recurrent VTE and ATE were included into recurrent VTE group as this event occurred first.
  3. Indicates statistical difference between patients without both VTE and ATE, and patients with recurrent VTE.
  4. Indicates statistical difference between patients with recurrent VTE and patients with ATE.
  5. The presented differences between groups remained statistically significant after adjustment for age, sex, diabetes and fibrinogen.